cytarabine has been researched along with sirolimus in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Amari, G; Bianchi, N; Catelani, G; D'Andrea, F; Gambari, R; Ghidini, E; Landi, M; Paola, P | 1 |
| Accetta, A; Borgatti, M; Brognara, E; Corradini, R; Gambari, R; Marchelli, R; Sforza, S; Tedeschi, T | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gagnon, A; Lau, S; Sorisky, A | 1 |
| Bagg, A; Carroll, M; Scialla, TJ; Simpson, SE; Xu, Q | 1 |
| Agis, H; Geissler, K; Mannhalter, C; Mayerhofer, M; Sagaster, V; Sillaber, C; Sperr, WR; Valent, P | 1 |
| Giles, FJ; Huang, P; Keating, MJ; Pelicano, H; Xu, RH; Zhang, H | 1 |
| Cebula, B; Janus, A; Linke, A; Robak, T; Smolewski, P | 1 |
| Carroll, M; Kasner, MT; Luger, SM; Perl, AE; Shank, D | 1 |
| Levis, M | 1 |
| Camara-Clayette, V; Hermine, O; Ribrag, V | 1 |
| Béné, MC; Bories, P; Bouscary, D; Cahn, JY; Chapuis, N; Chevallier, P; Delepine, R; Demur, C; Dreyfus, F; Ifrah, N; Lacombe, C; Lamy, T; Leguay, T; Mayeux, P; Merlat, A; Park, S; Prebet, T; Recher, C; Saint Marcoux, F; Tamburini, J; Vey, N; Witz, F | 1 |
| Baybis, M; Birnbaum, JF; Crino, PB; Goncharov, DA; Helfferich, J; Krymskaya, VP; Okochi, K; Orlova, KA; Parker, WE; Parker, WH; Strauss, KA | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Dreyling, M; Hess, G; Memmer, ML; Witzens-Harig, M | 1 |
| Avdonin, P; Bobrynina, V; Kalinina, I; Khachatryan, L; Maschan, A; Maschan, M; Nasedkina, T; Novichkova, G; Solopova, G | 1 |
| Arai, S; Kadowaki, T; Kubota, N; Kurokawa, M; Masamoto, Y; Sato, T; Takamoto, I | 1 |
| Carabasi, M; Carroll, M; Filicko-O'Hara, J; Flomenberg, N; Frey, NV; Hexner, EO; Jeschke, GR; Kasner, MT; Loren, AW; Luger, SM; Mangan, JK; Mick, R; Perl, AE; Wagner, JL; Weiss, M | 1 |
| Ali, H; Budde, E; Chen, R; Forman, SJ; Herrera, AF; Mei, M; Mokhtari, S; Nademanee, A; Nakamura, R; Popplewell, L; Salhotra, A; Sandhu, K; Stiller, T; Zain, J | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Cao, XX; Dai, JW | 1 |
3 review(s) available for cytarabine and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Examination; Clinical Trials as Topic; Cytarabine; Diagnosis, Differential; Drug Resistance; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Prognosis; Pyrimidines; Risk Factors; Sirolimus; Stem Cell Transplantation; Time Factors | 2003 |
Emerging agents for the treatment of mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Prognosis; Pyrazines; Recurrence; Salvage Therapy; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Watchful Waiting | 2012 |
6 trial(s) available for cytarabine and sirolimus
| Article | Year |
|---|---|
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Phosphorylation; Pilot Projects; Ribosomal Protein S6; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Everolimus; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2013 |
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large ce
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Disease-Free Survival; Feasibility Studies; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Research Design; Rituximab; Salvage Therapy; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Mitoxantrone; Phosphorylation; Pilot Projects; Remission Induction; Signal Transduction; Sirolimus | 2018 |
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Sirolimus; Survival Rate; Tacrolimus; Transplantation Conditioning | 2019 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
14 other study(ies) available for cytarabine and sirolimus
| Article | Year |
|---|---|
Synthesis of glycose carbamides and evaluation of the induction of erythroid differentiation of human erythroleukemic K562 cells.
Topics: Antineoplastic Agents; Cell Differentiation; Drug Screening Assays, Antitumor; Erythroid Cells; Galactose; Glucose; Humans; K562 Cells; Leukemia, Erythroblastic, Acute; Monosaccharides; Pentoses; Structure-Activity Relationship; Urea | 2009 |
New uracil dimers showing erythroid differentiation inducing activities.
Topics: Alkylation; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dimerization; Drug Design; Drug Screening Assays, Antitumor; Erythroid Cells; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Uracil | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Rapamycin-sensitive phase of 3T3-L1 preadipocyte differentiation after clonal expansion.
Topics: 3T3 Cells; Adipocytes; Animals; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Division; Cytarabine; Glycerolphosphate Dehydrogenase; Insulin; Kinetics; Mice; Protein Kinase Inhibitors; Protein Kinases; Receptors, Cytoplasmic and Nuclear; Ribosomal Protein S6 Kinases; Sirolimus; Stem Cells; TOR Serine-Threonine Kinases; Transcription Factors; Triglycerides | 2001 |
Survival of acute myeloid leukemia cells requires PI3 kinase activation.
Topics: Acute Disease; Animals; Cell Survival; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Everolimus; Humans; Leukemia, Myeloid; Mice; Mice, SCID; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Transplantation, Heterologous | 2003 |
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
Topics: Adenosine Triphosphate; Apoptosis; Cell Proliferation; Cytarabine; Drug Synergism; Energy Metabolism; Glycolysis; Humans; Leukemia; Lymphoma; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2005 |
Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
Topics: Adaptor Proteins, Signal Transducing; Caspase 3; Cell Cycle; Cell Cycle Proteins; Cell Death; Cell Proliferation; Cell Survival; Chromones; Cyclins; Cytarabine; Drug Synergism; Enzyme Inhibitors; Gene Expression; HL-60 Cells; Humans; Membrane Potential, Mitochondrial; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Protein Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; TOR Serine-Threonine Kinases | 2009 |
Phospho-specific flow: fixating on the target.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder.
Topics: Animals; Blotting, Western; Cell Movement; Cells, Cultured; Central Nervous System Diseases; Cytarabine; Female; Humans; Imidazoles; Immunohistochemistry; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Piperazines; Pregnancy; Seizures; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Control of thrombotic thrombocytopenic purpura by sirolimus in a child with juvenile myelomonocytic leukemia and somatic N-RAS mutation.
Topics: Age of Onset; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Genes, ras; Humans; Infant; Isotretinoin; Leukemia, Myelomonocytic, Juvenile; Mutation; Purpura, Thrombotic Thrombocytopenic; Sirolimus | 2014 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Adiponectin Enhances Quiescence Exit of Murine Hematopoietic Stem Cells and Hematopoietic Recovery Through mTORC1 Potentiation.
Topics: Adiponectin; Animals; Benzhydryl Compounds; Bone Marrow; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Epoxy Compounds; Fluorouracil; Gene Expression Regulation; Hematopoiesis; Hematopoietic Stem Cells; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Myeloablative Agonists; Poly I-C; Signal Transduction; Sirolimus; Whole-Body Irradiation | 2017 |
[Sirolimus successfully treated Erdheim-Chester disease with interferon and cytarabine treatment failure: a case report].
Topics: Cytarabine; Erdheim-Chester Disease; Humans; Interferon-alpha; Sirolimus; Treatment Failure | 2023 |